Report
BioNTech SE : Q2 results due 8 Aug – Expecting a solid quarter
>Expecting a quieter quarter after strong Q1 - Q1 was a strong quarter with vaccine-related revenues of close to € 6.4bn and an EBIT of € 4.75bn (74.6% margin). While we estimate that demand for the company’s coronavirus vaccine has been declining, also in light of the expectation of a new variant-specific vaccine, we still estimate c. € 3bn in coronavirus vaccine revenues for BioNTech for Q2. With operating expenses estimated to increase only gradually during FY 2022...
Underlying
BioNTech SE
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Oliver Metzger
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.